Vessi Medical

Executive Summary

Vessi Medical is developing a patented cryo-spray system for minimally invasive, non-contact ablation of hollow organs, initially targeting urological tissues such as the bladder. The platform enables office-based procedures without general anesthesia, potentially reducing complications and healthcare costs compared to conventional surgery. Founded in 2020 and based in Israel, the company is currently in Phase 1 clinical development. Its technology addresses a significant unmet need in non-muscle invasive bladder cancer and other urological conditions, where current treatments often require repeated surgeries under anesthesia. With a novel approach that combines cryoablation's benefits with a non-contact delivery system, Vessi aims to offer a safer, more accessible option for patients and lower system costs. The early-stage nature of the company presents both opportunity and risk, but the innovative platform could disrupt standard care if clinical data supports safety and efficacy.

Upcoming Catalysts (preview)

• H2 2026Phase 1 clinical trial results40% success
• TBDFDA IDE approval or Breakthrough Device designation50% success
• TBDStrategic partnership or licensing deal30% success